Clinic Workflow — Master Flowchart
This workflow illustrates the end-to-end patient journey through The Sandusky Dyslipidemia Model clinic, from referral receipt to ongoing management. For detailed documentation of each step, see the corresponding clinical documents linked below.
How to Read These Charts
The workflow is split into three charts that follow the patient in order. A dashed box at the end of a chart names the chart that picks up from there.
Entry point or goal reached Assessment step Decision question Treatment started or test ordered Caution: needs further evaluation High risk: urgent or aggressive action Labs, scheduling, or administrative step Continues in another chart on this page On a small screen, swipe sideways on a chart to see all of it.
Part 1 — Referral and Scheduling
flowchart TD
classDef entry fill:#2d6a4f,stroke:#1b4332,color:#fff
classDef assess fill:#264653,stroke:#16303a,color:#fff
classDef treat fill:#1565c0,stroke:#0d47a1,color:#fff
classDef caution fill:#c2410c,stroke:#9a3412,color:#fff
classDef urgent fill:#b42318,stroke:#7a1a12,color:#fff
classDef admin fill:#5f6770,stroke:#454c53,color:#fff
classDef link fill:#fff,stroke:#264653,stroke-width:2px,stroke-dasharray:5 4,color:#264653
A[Referral Received]:::entry --> B{Eligibility<br>Screen}
B -->|Meets criteria| C[Schedule New<br>Patient Visit]:::admin
B -->|Does not meet<br>criteria| D[Return to Referring<br>Provider with Explanation]:::admin
C --> E{Priority<br>Assessment}
E -->|Urgent: LDL ≥190,<br>post-ACS, TG ≥500| F[Schedule within<br>2 weeks]:::urgent
E -->|Standard| G[Schedule within<br>4–6 weeks]:::admin
F --> H[Pre-Visit:<br>Patient Instructions]:::admin
G --> H
H --> I[Nursing Intake<br>10 min]:::admin
I --> J[Provider Encounter<br>25 min]:::assess
J --> NEXT[Continue to Part 2:<br>Initial Visit]:::link
Part 2 — Initial Visit and Treatment Plan
flowchart TD
classDef entry fill:#2d6a4f,stroke:#1b4332,color:#fff
classDef assess fill:#264653,stroke:#16303a,color:#fff
classDef treat fill:#1565c0,stroke:#0d47a1,color:#fff
classDef caution fill:#c2410c,stroke:#9a3412,color:#fff
classDef urgent fill:#b42318,stroke:#7a1a12,color:#fff
classDef admin fill:#5f6770,stroke:#454c53,color:#fff
classDef link fill:#fff,stroke:#264653,stroke-width:2px,stroke-dasharray:5 4,color:#264653
J[Provider Encounter<br>25 min]:::assess --> K[History &<br>Physical Exam]:::assess
K --> L[Review Available<br>Labs & Records]:::assess
L --> M[Document Risk<br>Factors & Enhancers]:::assess
M --> N[PREVENT Risk<br>Calculation]:::assess
N --> O{Risk Category<br>Assignment}
O -->|Low risk<br>CAC=0 + ApoB neg| P[Consider<br>De-risking]:::entry
O -->|Borderline/<br>Intermediate| Q[Evaluate Risk<br>Enhancers]:::caution
O -->|High/Very High<br>or ASCVD| R[Aggressive<br>Treatment]:::urgent
P --> S[Lifestyle<br>Counseling]:::assess
Q --> T{Advanced Testing<br>Indicated?}
R --> U[Initiate/Optimize<br>Pharmacotherapy]:::treat
T -->|Yes| V[Order Advanced<br>Tools]:::treat
T -->|No| U
V --> W["ApoB / NMR /<br>Lp(a) / CAC"]:::assess
W --> X[Reassess Risk<br>Category]:::assess
X --> U
U --> Y[Treatment Plan<br>Documented]:::treat
S --> Y
Y --> Z[Order Labs for<br>Next Visit]:::admin
Z --> AA[Schedule<br>Follow-Up]:::admin
AA --> NEXT[Continue to Part 3:<br>Follow-Up Cycle]:::link
Part 3 — Follow-Up Cycle
flowchart TD
classDef entry fill:#2d6a4f,stroke:#1b4332,color:#fff
classDef assess fill:#264653,stroke:#16303a,color:#fff
classDef treat fill:#1565c0,stroke:#0d47a1,color:#fff
classDef caution fill:#c2410c,stroke:#9a3412,color:#fff
classDef urgent fill:#b42318,stroke:#7a1a12,color:#fff
classDef admin fill:#5f6770,stroke:#454c53,color:#fff
classDef link fill:#fff,stroke:#264653,stroke-width:2px,stroke-dasharray:5 4,color:#264653
AA[Schedule<br>Follow-Up]:::admin --> AB{Follow-Up<br>Type}
AB -->|New med or<br>dose change| AC[4–8 weeks]:::admin
AB -->|Titrating,<br>not stable| AD[3–6 months]:::admin
AB -->|At goal,<br>stable| AE[Annually]:::admin
AC --> AF[Follow-Up Visit<br>20 min]:::assess
AD --> AF
AE --> AF
AF --> AG{At Treatment<br>Goal?}
AG -->|Yes| AH[Continue Current<br>Therapy]:::entry
AG -->|No| AI[Escalate per<br>Treatment Pathway]:::caution
AH --> AA
AI --> U[Back to Part 2:<br>Initiate/Optimize<br>Pharmacotherapy]:::link
Workflow Cross-References
| Workflow Step | Detailed Documentation |
|---|---|
| Eligibility Screen | 02 — Patient Eligibility |
| History & Physical Exam | 03 — Initial Assessment, Sections 2.0–4.0 |
| PREVENT Risk Calculation | 04 — Risk Stratification |
| Risk Category Assignment | 04 — Risk Stratification |
| Advanced Tools | 06 — Advanced Tools |
| Treatment Plan | 05 — Treatment Pathways |
| Follow-Up Protocol | 12 — Follow-Up Protocol |
Special Pathways
The following specialty pathways branch from the master workflow at specific decision points:
| Pathway | Entry Point | Flowchart |
|---|---|---|
| Familial Hypercholesterolemia | LDL-C ≥ 190, tendon xanthomas, or family history of FH | FH Pathway Flow |
| Statin Intolerance | Reported statin intolerance during history or treatment | Statin Intolerance Flow |
| Treatment Escalation | Not at goal after initial or adjusted therapy | Treatment Escalation Flow |
| Risk Stratification Detail | PREVENT calculation and advanced testing decisions | Risk Stratification Flow |
| Advanced Tools Decision | Which advanced test to order and when | Advanced Tools Decision Flow |
Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-03-30 | Initial release |
| 1.1.0 | 2026-09-29 | Split into smaller charts so text renders at full size; fixed line breaks that printed as literal escape codes; accessible color palette and shared legend |